Jump to Main Content
Madi‐Ryuk and its active compound tannic acid suppress allergic inflammatory reactions in activated human mast cell HMC‐1
- Kim, Hee‐Yun, Jeong, Hyun‐Ja, Han, Na‐Ra, Jang, Jae‐Bum, Kim, Hyung‐Min
- Journal of food biochemistry 2018 v.42 no.6 pp. e12664
- active ingredients, anti-allergic agents, arthritis, caspase-1, cytokines, cytotoxicity, functional foods, gene expression, human cell lines, humans, macrophages, mast cells, messenger RNA, mitogen-activated protein kinase, nitric oxide, patients, signal transduction, signs and symptoms (animals and humans), tannins, transcription factor NF-kappa B
- Madi‐Ryuk (MDR) has been used for the treatment of arthritis as a health functional food and it alleviated clinical symptoms of patient with allergic disease. However, its scientific evidences have not been elucidated yet. Here we determined anti‐allergic inflammatory effect of MDR and its constituent tannic acid (TA) in activated human mast cell line HMC‐1 cells. In activated HMC‐1 cells, MDR and TA reduced thymic stromal lymphopoietin (TSLP) protein release and mRNA expression without affecting cytotoxicity. MDR and TA blocked activities of caspase‐1, nuclear factor‐κB, mitogen‐activated protein kinases, which are intracellular signaling pathways associated with increased TSLP levels in activated HMC‐1 cells. Levels of inflammatory cytokines were reduced by MDR and TA on activated HMC‐1 cells. Furthermore, MDR and TA reduced the nitric oxide production on activated macrophages. In conclusion, we clarified that MDR has a new anti‐allergic inflammatory effect through reducing TSLP. Our results suggest that MDR may be useful in the treatment of allergic inflammatory diseases. PRACTICAL APPLICATIONS: A health functional food, MDR has been clinically used for the treatment of arthritis. In addition, MDR has an anti‐allergic inflammatory effect through the blocking the inflammatory reaction signaling pathways. Therefore, our results indicate that MDR may be useful in the prevention and treatment of allergic inflammatory diseases.